Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lexaria Bioscience ( (LEXX) ) has shared an update.
Lexaria Bioscience has signed contracts with a contract research organization to conduct Human Pilot Study #7, a five-week, three-arm trial comparing two oral DehydraTECH-semaglutide formulations with Novo Nordisk’s commercially available Wegovy tablets under fasted conditions. The study will assess safety, tolerability and pharmacokinetics, aiming to match or exceed the performance of existing oral semaglutide products while maintaining favorable safety profiles seen in earlier Lexaria GLP-1 work.
In a first for the company, Lexaria will test a DehydraTECH-semaglutide tablet designed to mimic some stomach-adhering and focal-release properties of Rybelsus and Wegovy tablets, and will evaluate both tablet and capsule formats formulated with SNAC over a multi-dose, multi-week regimen to reach steady-state drug levels. The fully funded study, if successful, is expected to strengthen Lexaria’s clinical data package and potentially enhance its appeal to pharmaceutical partners seeking commercial applications of its DehydraTECH platform in the competitive GLP-1 obesity and diabetes market.
The most recent analyst rating on (LEXX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp., based in Kelowna, British Columbia, is a drug delivery technology company focused on its patented DehydraTECH platform for oral administration of pharmaceuticals. The technology is designed to improve bio-absorption, reduce side-effects and enhance delivery of various drugs, and is supported by an in-house research lab and a portfolio of 65 granted patents worldwide.
Average Trading Volume: 180,331
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.41M
For an in-depth examination of LEXX stock, go to TipRanks’ Overview page.